Goldman Sachs Group Analysts Give AstraZeneca (AZN) a GBX 4,080 Price Target
AstraZeneca (LON:AZN) has been given a GBX 4,080 ($53.31) price objective by Goldman Sachs Group in a report issued on Thursday, September 20th. The brokerage currently has a “sell” rating on the biopharmaceutical company’s stock. Goldman Sachs Group’s price objective would suggest a potential downside of 26.43% from the company’s previous close.
Other equities research analysts have also recently issued reports about the stock. Shore Capital reiterated a “hold” rating on shares of AstraZeneca in a research report on Tuesday, June 5th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of AstraZeneca in a research report on Thursday, July 26th. Deutsche Bank reiterated a “buy” rating and issued a GBX 6,000 ($78.40) target price on shares of AstraZeneca in a research report on Friday, July 27th. Cfra set a GBX 5,000 ($65.33) price objective on shares of AstraZeneca and gave the stock a “neutral” rating in a research report on Wednesday, May 23rd. Finally, UBS Group restated a “neutral” rating and set a GBX 5,600 ($73.17) price objective on shares of AstraZeneca in a research report on Monday, July 2nd. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of GBX 5,700.70 ($74.49).
Shares of LON AZN traded down GBX 70 ($0.91) during mid-day trading on Thursday, reaching GBX 5,546 ($72.47). The company’s stock had a trading volume of 2,077,869 shares, compared to its average volume of 2,310,000. AstraZeneca has a 1-year low of GBX 4,260 ($55.66) and a 1-year high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: How to Use the New Google Finance Tool
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.